Insight Molecular Diagnostics, Inc. (IMDX)
4.14
+0.13
(+3.24%)
USD |
NASDAQ |
Sep 22, 16:00
4.115
-0.02
(-0.60%)
After-Hours: 20:00
Insight Molecular Diagnostics Total Assets (Quarterly) : 29.44M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.44M |
| March 31, 2026 | 40.43M |
| December 31, 2025 | 25.76M |
| September 30, 2025 | 43.94M |
| June 30, 2025 | 50.52M |
| March 31, 2025 | 60.36M |
| December 31, 2024 | 35.08M |
| September 30, 2024 | 70.22M |
| June 30, 2024 | 74.72M |
| March 31, 2024 | 70.97M |
| December 31, 2023 | 74.89M |
| September 30, 2023 | 81.59M |
| June 30, 2023 | 87.54M |
| March 31, 2023 | 82.80M |
| December 31, 2022 | |
| September 30, 2022 | 157.34M |
| June 30, 2022 | 171.05M |
| March 31, 2022 | 146.27M |
| December 31, 2021 | 159.56M |
| September 30, 2021 | 168.34M |
| June 30, 2021 | 177.38M |
| March 31, 2021 | 129.30M |
| Date | Value |
|---|---|
| December 31, 2020 | 55.42M |
| September 30, 2020 | 57.78M |
| June 30, 2020 | 63.46M |
| March 31, 2020 | 59.50M |
| December 31, 2019 | 39.86M |
| September 30, 2019 | 32.77M |
| June 30, 2019 | 37.67M |
| March 31, 2019 | 41.68M |
| December 31, 2018 | 9.518M |
| September 30, 2018 | 12.90M |
| June 30, 2018 | 12.20M |
| March 31, 2018 | 15.58M |
| December 31, 2017 | 10.22M |
| September 30, 2017 | 14.25M |
| June 30, 2017 | 12.14M |
| March 31, 2017 | 15.17M |
| December 31, 2016 | 14.45M |
| September 30, 2016 | 16.86M |
| June 30, 2016 | 7.424M |
| March 31, 2016 | 9.647M |
| December 31, 2015 | 12.73M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 392.02M |
| Agenus, Inc. | 172.69M |
| Amgen, Inc. | 95.64B |
| Anika Therapeutics, Inc. | 183.47M |
| BioCryst Pharmaceuticals, Inc. | 557.85M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 50.74M |
| Shareholders Equity (Quarterly) | -21.30M |
| Debt to Equity Ratio | -0.1232 |
| Current Ratio | 1.997 |
| Net Debt Paydown Yield | 0.09% |